Furthermore, we observed that treatment (in vivo), with an anti-JAM-A monoclonal antibody (αJAM-A moAb) had an inhibitory effect on tumour progression in a mouse xenograft MM model [190]. The gene discussed is F11R; the disease is Miyoshi myopathy.